You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Developing a Nutraceutical Product against Ototoxicity

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARYDespite recent advances in cancer therapiesplatinum based drugs are still widely used for the treatment of solid tumorsA primary example is cisplatinwhich is frequently used to treat lungbladdertesticularand cervical cancersHoweverlimitations of this therapy include the development of drug resistance in cancer cells as well as severe side effectssuch as nephrotoxicity and neurotoxic ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Biologically Targeted Vaccine for Chikungunya

    SBC: PRECISION VIROLOGICS INC            Topic: NIAID

    PROJECT SUMMARY ABSTRACT Chikungunya virusCHIKVis a mosquito transmitted alphavirus that causes explosive epidemics of a severe febrile illness characterized by debilitating polyarthralgia in humansCHIKV caused an estimatedmillion new cases in India alone inand has the potential to spread globally because of the distribution and abundance of its mosquito vectorsAedes aegypti and Aedes albopictusDu ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Oxidation-resistant Anti-protease Therapy

    SBC: LEXEO Therapeutics LLC            Topic: NHLBI

    AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stressLEXthest LEXEO productis ast in classnext generation gene therapy treatment for alphaantitrypsinAATdeficiencyan autosomal recessive hereditary disorder associated with low serum levels of AATAATSERPINAakDa serine antiprotease produced by th ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Increasing Access and Developing Predictors for Colorectal Cancer Screening for Minority and Medicaid Clients

    SBC: Witness CARES, LLC            Topic: 102

    ABSTRACT African Americans havehigher incidence andhigher death rates from CRC than any other ethnic racial groupSimilarlylower socioeconomic statusSESis also associated with higher CRC incidence and mortalityBoth of these groups are overrepresented in Medicaid populationsScreening colonoscopy is a cost effective cancer prevention and control strategyleading to CRC preventione gremoval of precance ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel remedy for periodontal bone loss

    SBC: Periomics Care LLC            Topic: NIDCR

    Abstract Periodontitis is a common chronic inflammatory disease characterized by destruction of the supporting structures of the teeththe periodontal ligament and alveolar boneThe total prevalence of periodontitis in adults agedyears and older wasrepresenting aboutmillion adults agedyears and olderandin adults agedyears and older in the U SEpidemiological data confirm that diabetes is a major risk ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a bioconjugate vaccine against Group B Streptococcus

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Streptococcus agalactiaecommonly referred to as Group B StreptococcusGBSis a leading cause of neonatal meningitis and sepsis worldwide as well as an agent of invasive disease in both pregnant and non pregnant adultsGBS neonatal disease manifests as early onsetdefined as disease within the first six days after birthor late onsetdefined as disease occurring after the first week of li ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency

    SBC: LEXEO Therapeutics LLC            Topic: 400

    AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using in vivo gene therapy technologies to treat disorders of unmet medical needLEXEO is developing an in vivo gene therapy strategy as a preventative therapy to protect individuals with aldehyde dehydrogenaseALDHdeficiency from the high risk for esophageal cancerAs the next step in the development paththe goal of this ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Use of mimotope vaccine technology to develop vaccines against bacterial pathogens

    SBC: ZenVax LLC            Topic: NIAID

    ABSTRACT This Small Business Technology TransferSTTRPhase I proposal is in response toNIH NIAID Research Topics in Division of Microbiology and Infectious Diseases and Bacteriology and Mycology BranchVaccine for prevention of human Q feverQ fever is a worldwide zoonotic disease that is caused by the obligate intracellular Gram negative bacteriumCoxiella burnetiiThe highly infectious nature of Cbur ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE

    SBC: Mitochondria in Motion, Inc.            Topic: NINDS

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn IIMD Mitochondria in MotionIncWashington University in St Louis School of Medicine AbstractThere are a number of rare neurodegenerative diseasesincluding Amyotrophic Lateral SclerosisALSand Huntington s DiseaseHDfor which there is no available or effective therapy and which lead to significant morbidity and mortality ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Design and Development of Targeted-Liposome for drug delivery to lung cancer by exploiting a vulnerability induced by radiotherapy

    SBC: Medical Guidance Systems LLC            Topic: 102

    Abstract The proposed drug development will result in the design and development of a ligand targeted liposomeLTLthat will aid in the targeted delivery of therapeutics to patients with Non Small Cell Lung CancerNSCLCWe propose an innovative active targeting strategy and our technology exploits the stress response that occurs within the cancer cells following exposure to ionizing radiationThis lipo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government